Moreover, baseline IHC scores of CD3+ and sublining CD68+ arose as useful biomarkers of treatment response to first-line DMARDs in PsA and Abneg RA respectively, suggesting the need to include both parameters in more extensive future synovial tissue biopsy-driven clinical trials for these inflammatory joint conditions. This evidence concerns the gene CD68 and rheumatoid arthritis.